1
|
Odiase O, Noah-Vermillion L, Simone BA, Aridgides PD. The Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer: A Focused Review. Front Oncol 2021; 11:663749. [PMID: 34123823 PMCID: PMC8189418 DOI: 10.3389/fonc.2021.663749] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 04/21/2021] [Indexed: 12/31/2022] Open
Abstract
In 2011 the Food and Drug Administration (FDA) approved anti-vascular endothelial growth factor (VEGF) therapy, bevacizumab, for intractable melanoma. Within the year, immunotherapy modulators inhibiting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) were approved in addition to programmed death-ligand 1 (PD-L1) antibodies in 2012. Since then, research showing the effectiveness of targeted therapies in a wide range of solid tumors has prompted studies incorporating their inclusion as part of upfront management as well as refractory or relapsed disease. For treatment of cervical cancer, which arises from known virus-driven oncogenic pathways, the incorporation of targeted therapy is a particularly attractive prospect. The current standard of care for locally advanced cervical cancer includes concurrent platinum-based chemotherapy with radiation therapy (CRT) including external beam radiation therapy (EBRT) and brachytherapy. Building upon encouraging results from trials testing bevacizumab or immunotherapy in recurrent cervical cancer, these agents have begun to be incorporated into upfront CRT strategies for prospective study. This article will review background data establishing efficacy of angiogenesis inhibitors and immunotherapy in the treatment of cervical cancer as well as results of prospective studies combining targeted therapies with standard CRT with the aim of improving outcomes. In addition, the role of immunotherapy and radiation on the tumor microenvironment (TME) will be discussed.
Collapse
Affiliation(s)
| | | | | | - Paul D. Aridgides
- Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, United States
| |
Collapse
|
2
|
Pak R, Sadykova T, Kaidarova D, Gultekin M, Kasimova G, Tanabayeva S, Ussebayeva N, Tazhiyeva A, Senbekov M, Fakhradiyev I. The Life Quality and Sexual Function of Women Underwent Radical Hysterectomy. Asian Pac J Cancer Prev 2021; 22:581-589. [PMID: 33639677 PMCID: PMC8190359 DOI: 10.31557/apjcp.2021.22.2.581] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Indexed: 11/25/2022] Open
Abstract
Background: Up to date, there no studies were conducted on the quality of life (QL) and sexual function (SF) of women from Kazakhstan treated for cervical cancer. The study was aimed at the assessment of the QL and SF of women of the Kazakh population who underwent radical hysterectomy compared with chemo-radiotherapy group. Methods: The study was conducted prospectively on 157 women of the Kazakh population. 92 women underwent radical hysterectomy (RH) and 65 underwent chemo-radiotherapy (CRT). The information was collected before treatment (T1), 6 months (T2) and 12 months (T3) after treatment. Results: The women’s average age was 41.12 ± 5.4 in the RH group and 47.24 ± 6.1 in the CRT group (p = 0.2). We did not detect significant differences between both groups according to the QLQ C-30 questionnaire (T1). The differences between the RH and CRT groups (p≤0,05) were observed in terms of physical functioning, fatigue, nausea and vomiting, pain during the T2 period. High rates of emotional functioning (p = 0.03), global health and QL (p = 0.02), and symptoms of fatigue (p = 0.04) were detected in the RH group compared to the CRT group during T3. However, pain symptoms (p = 0.001), nausea and vomiting and loss of appetite (p = 0.03) were dominated the CRT group. According to the results of FSFI-6 in the RH group, indicators for the domains “desire” (p = 0.02), “excitement” (p = 0.03), and “orgasm” (p = 0.05) were high, unlike in the CRT group during the T3 period. Nevertheless, the number of complains on the ‘pain during intercourse’ in the CRT group was higher than in the RH group (p = 0.001). Conclusion: Women who underwent RH had better health scores, global health status, and SF compared with patients treated with CRT.
Collapse
Affiliation(s)
- Roza Pak
- Kazakh Institute of Oncology and Radiology. Almaty, Kazakhstan
| | - Tolkyn Sadykova
- S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
| | | | - Murat Gultekin
- Department of Obstetrics and Gynecology, Division of Gynaecological Oncology, Hacettepe, University Faculty of Medicine, Ankara, Turkey
| | | | - Shynar Tanabayeva
- S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
| | - Naylia Ussebayeva
- Kazakh Medical University of Continuing Education, Almaty, Kazakhstan
| | - Aigul Tazhiyeva
- S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
| | - Maksut Senbekov
- S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
| | - Ildar Fakhradiyev
- S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
| |
Collapse
|
3
|
Fayez S, Bruhn T, Feineis D, Assi LA, Awale S, Bringmann G. Ancistrosecolines A-F, Unprecedented seco-Naphthylisoquinoline Alkaloids from the Roots of Ancistrocladus abbreviatus, with Apoptosis-Inducing Potential against HeLa Cancer Cells. JOURNAL OF NATURAL PRODUCTS 2020; 83:1139-1151. [PMID: 32125158 DOI: 10.1021/acs.jnatprod.9b01168] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Ancistrosecolines A-F (8-13) are the first seco-type naphthylisoquinoline alkaloids discovered in Nature. In all these novel compounds, the tetrahydroisoquinoline ring is cleaved, with loss of C-1. They were isolated from the root bark of Ancistrocladus abbreviatus (Ancistrocladaceae), along with 1-nor-8-O-demethylancistrobrevine H (14), which is the first naturally occurring naphthylisoquinoline lacking the otherwise generally present methyl group at C-1. The stereostructures of the new alkaloids were established by HRESIMS, 1D and 2D NMR, oxidative degradation, and experimental and quantum-chemical ECD investigations. Ancistrosecolines A-F (8-13) and 1-nor-8-O-demethylancistrobrevine H (14) are typical Ancistrocladaceae-type metabolites, i.e., oxygenated at C-6 and S-configured at C-3, belonging to the subclasses of 7,1'- and 7,8'-coupled alkaloids. The biaryl linkages of 8-14 are rotationally hindered due to bulky ortho-substituents next to the axes. Owing to the constitutionally unsymmetric substitution patterns on each side of the axis, this C-C single bond represents an element of chirality in 1-nor-8-O-demethylancistrobrevine H (14) and in ancistrosecolines A-D (8-11). In ancistrosecolines E (12) and F (13), however, the likewise rotationally hindered biaryl axes do not constitute chiral elements, due to a symmetric substitution pattern, with its identical two methoxy functions at C-6 and C-8 in the phenyl subunit. And these two methoxy groups are, for the first time, not constitutionally heterotopic, but diastereotopic to each other. Ancistrosecoline D (11) exhibits strong cytotoxicity against HeLa cervical cancer cells. As visualized by Hoechst nuclei staining and by real-time imaging experiments, 11 induced massive nuclei fragmentation in HeLa cells, leading to apoptotic cell death.
Collapse
Affiliation(s)
- Shaimaa Fayez
- Institute of Organic Chemistry, University of Würzburg, Am Hubland, D-97074 Würzburg, Germany
- Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Organization of African Unity Street 1, 11566 Cairo, Egypt
| | - Torsten Bruhn
- Federal Institute for Risk Assessment, Max-Dohrn-Straße 8-10, D-10589 Berlin, Germany
| | - Doris Feineis
- Institute of Organic Chemistry, University of Würzburg, Am Hubland, D-97074 Würzburg, Germany
| | - Laurent Aké Assi
- Centre National de Floristique, Conservatoire et Jardin Botaniques, Université d'Abidjan, Abidjan 08, Ivory Coast
| | - Suresh Awale
- Division of Natural Drug Discovery, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
| | - Gerhard Bringmann
- Institute of Organic Chemistry, University of Würzburg, Am Hubland, D-97074 Würzburg, Germany
| |
Collapse
|
4
|
Lu F, Cui D, Mu B, Zhao L, Mu P. Downregulation of TMOD1 promotes cell motility and cell proliferation in cervical cancer cells. Oncol Lett 2020; 19:3339-3348. [PMID: 32218869 DOI: 10.3892/ol.2020.11410] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2017] [Accepted: 01/23/2020] [Indexed: 12/30/2022] Open
Abstract
Tropomodulin-1 (TMOD1) is a key regulator of actin dynamics, which caps the pointed end of actin filaments. TMOD1 has been reported to be involved in several cellular processes, including neurite outgrowth, spine formation and cell migration. Increasing evidence demonstrates that TMOD1 is implicated in several aspects of cancer development. The present study aimed to investigate the role of TMOD1 in cervical cancer. HeLa and CaSki cell lines, derived from human cervical cancer, were used to evaluate the function of TMOD1. Cell motility was measured via a wound-healing assay, with the TMOD1 short hairpin (sh)RNAs transfected cells. Subsequently, cell proliferation was assessed using low serum cell culture condition, while cell cycle distribution was analyzed via flow cytometry. The results demonstrated that downregulated TMOD1 promoted cell motility and proliferation, which is attributed to promotion of G1/S phase transition in HeLa and CaSki cells. Furthermore, it was indicated that co-expression of shRNA resistant TMOD1 rescued these phenomena. The clinical data demonstrated that high TMOD1 expression is associated with good pathological status in patients with cervical cancer. Overall, the results of the present study indicated that TMOD1 may act as a tumor suppressor in cervical cancer, whereby its downregulated expression was demonstrated to have direct effects on cell motility and cell proliferation. These results provide new evidence for the prognostic prediction of cervical cancer, which may serve as a promising therapeutic strategy for patients with cervical cancer.
Collapse
Affiliation(s)
- Fangjin Lu
- Department of Pharmacology, Shenyang Medical College, Shenyang, Liaoning 110034, P.R. China
| | - Dandan Cui
- Department of Maternity, Shenyang Women and Children's Health Hospital, Shenyang, Liaoning 110014, P.R. China
| | - Bin Mu
- Shanghai Zhaohui Pharmaceutical Co., Ltd., Shanghai 201900, P.R. China
| | - Lu Zhao
- Department of Biochemistry and Molecular Biology, Basic Medical School, Shenyang Medical College, Shenyang, Liaoning 110034, P.R. China
| | - Ping Mu
- Department of Biochemistry and Molecular Biology, Basic Medical School, Shenyang Medical College, Shenyang, Liaoning 110034, P.R. China.,Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Aichi 4660065, Japan
| |
Collapse
|
5
|
Shanshan H, Lan X, Xia L, Huang W, Meifang Z, Ling Y. Inhibition of protease-activated receptor-2 induces apoptosis in cervical cancer by inhibiting signal transducer and activator of transcription-3 signaling. J Int Med Res 2019; 47:1330-1338. [PMID: 30700181 PMCID: PMC6421370 DOI: 10.1177/0300060518820440] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Objective The present study explored how the inhibition of protease-activated
receptor-2 (PAR-2) induced proliferation and apoptosis in
cervical cancer in vitro and in
vivo. Methods mRNA and protein expression of PAR2 and signal transducer and
activator of transcription-3 (STAT-3) was determined by
quantitative real-time PCR and western blotting. The
proliferation and apoptosis of cervical cancer cells were
assayed by the cell counting kit-8 kit, flow cytometry, and
western blotting. The effects of PAR2 inhibition on cervical
cancer were also examined in BALB/c nude mice in
vivo. Results SLIGRL-NH2 (SL), a selective PAR-2 agonist, promoted proliferation
and inhibited apoptosis of healthy cervical cancer cells and
HeLa cells, while the PAR-2 antagonist FSLLRY-NH2 (FS) inhibited
proliferation and led to apoptosis. SL also promoted the
activation of STAT-3, while FS inhibited it and inhibited cancer
growth in vivo. Conclusion FS inhibited cervical cancer by reducing proliferation and inducing
apoptosis by interfering with STAT-3 signaling.
Collapse
Affiliation(s)
- Hu Shanshan
- Department of Gynecology, Wuhan University of Science and Technology Hospital, Wuhan City, Hubei, China
| | - Xiao Lan
- Department of Gynecology, Wuhan University of Science and Technology Hospital, Wuhan City, Hubei, China
| | - Li Xia
- Department of Gynecology, Wuhan University of Science and Technology Hospital, Wuhan City, Hubei, China
| | - Wang Huang
- Department of Gynecology, Wuhan University of Science and Technology Hospital, Wuhan City, Hubei, China
| | - Zuo Meifang
- Department of Gynecology, Wuhan University of Science and Technology Hospital, Wuhan City, Hubei, China
| | - Yin Ling
- Department of Gynecology, Wuhan University of Science and Technology Hospital, Wuhan City, Hubei, China
| |
Collapse
|
6
|
Degu A, Njogu P, Weru I, Karimi P. Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya. GYNECOLOGIC ONCOLOGY RESEARCH AND PRACTICE 2017; 4:15. [PMID: 29075505 PMCID: PMC5648473 DOI: 10.1186/s40661-017-0054-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Accepted: 10/13/2017] [Indexed: 02/07/2023]
Abstract
Background Although cervical cancer is preventable, it is still the second leading cause of cancer deaths among women in the world. Further, it is estimated that around 5–10% of hospital admissions are due to drug related problems (DRPs), of which 50% are avoidable. In cancer therapy, there is an immense potential for DRPs due to the high toxicity of most chemotherapeutic regimens. Hence, this study sought to assess DRPs among patients with cervical cancer at Kenyatta National Hospital (KNH). Methods A cross-sectional study was conducted at the oncology units of KNH. A total of 81 study participants were recruited through simple random sampling. Data were collected from medical records and interviewing patients. The appropriateness of medical therapy was evaluated by comparing with National Compressive Cancer Network and European Society for Medical Oncology practice guideline of cervical cancer treatment protocol. The degree of adherence was determined using eight-item Morisky medication adherence scale. The likelihood of drug interaction was assessed using Medscape, Micromedex and Epocrates drug interaction checkers. The data were entered in Microsoft Excel and analysed using statistical software STATA version 13.0. Descriptive statistics such as mean, percent and frequency were used to summarise patients’ characteristics. Univariable and multivariable binary logistic regression were used to investigate the potential predictors of DRPs. Result A total of 215 DRPs were identified from 76 patients, translating to a prevalence of 93.8% and a mean of 2.65 ± 1.22 DRPs. The predominant proportion of DRPs (48.2%) was identified in patients who had been treated with chemoradiation regimens. Adverse drug reactions 56(69.1%) and drug interactions 38(46.9%) were the most prevalent DRPs. Majority (67.9%) of the study population were adherent to their treatment regimens. Forgetfulness 18(69.2%), expensive medications 4(15.4%) and side effects of medications 4(15.4%) were the main reasons for medication non-adherence. Patients with advanced stage cervical cancer were 15.4 times (AOR = 15.4, 95% CI = 1.3–185.87, p = 0.031) more likely to have DRPs as compared to patients with early stage disease. Conclusion Adverse drug reactions, drug interactions, and need of additional drug therapy were the most common DRPs identified among cervical cancer patients. Advanced stage cervical cancer was the only predictor of DRPs.
Collapse
Affiliation(s)
- Amsalu Degu
- Department of Pharmaceutics and Pharmacy Practice, University of Nairobi, College of Health Sciences, School of Pharmacy, P.O. Box 19676-00202, Nairobi, Kenya
| | - Peter Njogu
- Department of Pharmaceutical Chemistry, University of Nairobi, College of Health Sciences, School of Pharmacy, Nairobi, 19676-00202 Kenya
| | - Irene Weru
- Kenyatta National Hospital, Division of Pharmacy, Nairobi, 20723-00202 Kenya
| | - Peter Karimi
- Department of Pharmaceutics and Pharmacy Practice, University of Nairobi, College of Health Sciences, School of Pharmacy, P.O. Box 19676-00202, Nairobi, Kenya
| |
Collapse
|
7
|
Lee KM, Lee K, Choi YK, Choi YJ, Seo HS, Ko SG. SH003‑induced G1 phase cell cycle arrest induces apoptosis in HeLa cervical cancer cells. Mol Med Rep 2017; 16:8237-8244. [PMID: 28944910 DOI: 10.3892/mmr.2017.7597] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Accepted: 05/03/2017] [Indexed: 11/05/2022] Open
Abstract
Cervical cancer is a prevalent disease that may lead to mortality in women. In spite of the development of common therapeutic agents to treat cancer, there are several limitations of their use owing to side effects and drug resistance, which may induce cancer recurrence. The anticancer effects of the new herbal mixture SH003 (comprising Astragalus membranaceus, Angelica gigas and Trichosanthes kirilowii Maximowicz) have been examined in various types of cancer. Thus, the present study hypothesized that SH003 may be an effective treatment for cervical cancer. SH003 treatment inhibited the growth of HeLa cells, whereas it did not affect the growth of rat intestinal epithelial cells. In addition, SH003 treatment increased the expression of apoptosis‑related proteins and promoted apoptotic cell death in HeLa cells. SH003 treatment also led to G1 phase arrest in HeLa cells. Furthermore, SH003 treatment induced the production of reactive oxygen species (ROS); however, ROS production did not appear to be related to SH003‑mediated apoptosis. Results from the present study indicated that the SH003‑induced inhibition of HeLa cell growth may be mediated through G1 phase arrest and extrinsic apoptosis, suggested that SH003 may be a potential treatment for cervical cancer.
Collapse
Affiliation(s)
- Kang Min Lee
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02247, Republic of Korea
| | - Kangwook Lee
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02247, Republic of Korea
| | - Youn Kyung Choi
- Jeju International Marine Science Center for Research & Education, Korea Institute of Ocean Science and Technology, Jeju 63349, Republic of Korea
| | - Yu-Jeong Choi
- Department of Cancer Preventive Material Development, Graduate School, Kyung Hee University, Seoul 02247, Republic of Korea
| | - Hye-Sook Seo
- Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02247, Republic of Korea
| | - Seong-Gyu Ko
- Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul 02247, Republic of Korea
| |
Collapse
|
8
|
Fertility Sparing Surgery for Cervical Cancer: Practice Points. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY 2017. [DOI: 10.1007/s40944-017-0144-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|